LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Small Molecule Approaches to Regenerative Therapies
Fundamentals, Opportunities and Challenges
- 1st Edition - February 1, 2099
- Editors: Graham M. Wynne, Lorna R. Fiedler
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 8 3 7 5 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 8 5 1 2 - 3
Small Molecule Approaches to Regenerative Therapies:Fundamentals, Opportunities and Challenges provides comprehensive coverage of a new and emerging area for the development of… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteSmall Molecule Approaches to Regenerative Therapies:Fundamentals, Opportunities and Challenges provides comprehensive coverage of a new and emerging area for the development of novel therapeutics. The approach offers significant potential for paradigm changing drugs in areas of healthcare which have proven challenging or recalcitrant to conventional strategies. Following over 50 years of research in the area, pioneering work using stem cell therapies has demonstrated promise in a number of disease areas, but it has been challenging to translate this approach into clinically meaningful outcomes. Approaches using small molecules, where the translational pathway to the clinic is much better understood, build on a better understanding of exogenous stem cell mediated therapeutic mechanisms. A comprehensive overview of the background, status, and potential for small molecule regenerative medicines is provided across a range of therapeutic areas, with multiple case studies. The unique challenges for drug discovery which are specific to the regenerative medicine arena are highlighted. This book will be a valuable resource to researchers working in medicinal chemistry, pharmacology and biotechnology, in academia and industry.
· Reviews the field of regenerative medicine, starting with basic biology with a focus on translational aspects, and ultimately focusing on the utility of small molecules to modulate endogenous stem and progenitor cells with application across a wide range of diseases.
· Includes perspectives on how small molecule therapies are conventionally developed in classical path/cascades and how this differs in the context of regenerative medicine.
· Discusses how to tailor drug discovery workflows to address challenges will be presented, along with specific case studies.
· Presents a selection of case studies across multiple therapeutic areas to demonstrate and reinforce the points highlighted elsewhere in the text, how they have been applied in practice, and key learnings for future studies
· Includes perspectives on how small molecule therapies are conventionally developed in classical path/cascades and how this differs in the context of regenerative medicine.
· Discusses how to tailor drug discovery workflows to address challenges will be presented, along with specific case studies.
· Presents a selection of case studies across multiple therapeutic areas to demonstrate and reinforce the points highlighted elsewhere in the text, how they have been applied in practice, and key learnings for future studies
Researchers working in medicinal chemistry, involved in all areas of pre-clinical drug discovery.
- No. of pages: 420
- Language: English
- Edition: 1
- Published: February 1, 2099
- Imprint: Elsevier
- Paperback ISBN: 9780323983754
- eBook ISBN: 9780323985123
GW
Graham M. Wynne
Graham’s most recent role is VP Research at OxStem Ltd. He has over 20 years of drug discovery experience gained in small to medium sized biopharma companies and in academia. His recent work has encompassed multiple therapeutic areas, including oncology, muscular dystrophy and regenerative medicine and he has co-founded several companies. Graham established and led the medicinal chemistry team at Summit Therapeutics which discovered ezutromid, a potential first-in-class treatment for Duchenne Muscular Dystrophy which progressed to Phase 2 clinical trials. At OSI Pharmaceuticals Inc his group were responsible for the discovery of OSI-930, a dual kit-KDR kinase inhibitor which progressed into Phase 1 clinical trials. Graham gained his PhD in Chemistry from the University of Nottingham and undertook post-doctoral studies at ANU, Canberra. He has co-authored or is inventor on around 70 papers and patents.
LF
Lorna R. Fiedler
Lorna’s most recent role is Associate Director Research and Heart Failure Programme Lead at OxStem Ltd. She has 15 years experience across biotech and academic sectors and a PhD in vascular biology. Her expertise lies in cardiovascular and neurodegenerative disease biology and therapeutics, and in translating innovative science into drug discovery programmes. Lorna previously held a research fellow and project lead position at Duke-National University of Singapore Medical School, investigating the molecular mechanisms underlying heart failure. She also led the Biology team at Imperial College London, where she developed a cardioprotective small molecule, now in IND-enabling studies and for which she is a co-inventor on the patent. This work was featured in FierceBiotech and was published in 2019 Cell Stem Cell with an accompanying commentary. She also holds an academic position at Oxford University, is an Associate Editor for Bioscience reports and is a key opinion leader board member for Oxford Global drug discovery series.